Compare MTA & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTA | BWAY |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | Canada | Israel |
| Employees | N/A | 129 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.4M | 674.2M |
| IPO Year | 2017 | N/A |
| Metric | MTA | BWAY |
|---|---|---|
| Price | $7.51 | $16.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 356.7K | 127.0K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $81.63 | $309.69 |
| Revenue Next Year | $62.44 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $9.98 |
| 52 Week High | $9.25 | $26.63 |
| Indicator | MTA | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 58.91 | 53.94 |
| Support Level | $7.08 | $14.56 |
| Resistance Level | $7.73 | $16.63 |
| Average True Range (ATR) | 0.33 | 0.61 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 80.43 | 53.44 |
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.